Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): Focus on targeted therapies

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 1, 2012, Pages 38-48

  Cappetta, Alessandro ^a   Lonardi, Sara ^a   Pastorelli, Davide ^a   Bergamo, Francesca ^a   Lombardi, Giuseppe ^a   Zagonel, Vittorina ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Gastric cancer; Gastro oesophageal junction cancer; Monoclonal antibody; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANOREXIA; ARTERY THROMBOSIS; BLEEDING; COLON PERFORATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LOWER ESOPHAGUS SPHINCTER; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PROTEINURIA; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855958099     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.12.006     Document Type: Review

References (71)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Levi F., Lucchini F., Gonzalez J.R., et al. Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 2004, 15:338-345.
3. Arak A., Kull K. Factors influencing survival of patients after radical surgery for gastric cancer. Ann Oncol 1994, 33:913-920.
4. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20.
5. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
6. Lordick F., Siewert J.R. Recent advances in multimodal treatment for gastric cancer: a review. Gastric Cancer 2005, 8:78-85.
7. Wagner A.D., Grothe W., Behl S., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005, 18:CD004064.
8. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line chemotherapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 2006, 24:4991-4997.
9. Mendelson J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002, 20:1S-13S.
10. Perez-Soler R., Saltz L. Cutaneous adverse effect with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005, 23:5235-5246.
11. Rojo F., Albanell J., Sauleda S., et al. Characterization of epidermal growth factor (EGF) receptor and transforming growth factor (TGF) alpha expression in gastric cancer and its association with activation of mitogen-activated protein kinase (MAPK). Proc Am Soc Clin Oncol 2001, 20(430a):A1717.
12. Gamboa-Dominguez A., Dominguez-Fonseca C., Quintanilla-Martinez L., et al. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Mod Pathol 2004, 17:579-584.
13. Goldstein N.I., Prewett M., Zuklys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1:1311-1318.
14. Imai K., Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006, 6:714-727.
15. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007, 25:2171-2177.
16. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
17. Stein A., Al-Batran S.E., Arnold D., et al. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proc GI ASCO 2007, 47.
18. Lin L., Hecht J. A phase III trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal junction. Proc Am Soc Clin Oncol 2000, 19:A1130.
19. Tebbutt N.C., Sourjina T., Strickland A.H., et al. ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer-final results of a multicentre phase II trial by the AGITG. Proc GI ASCO 2008, 87. [Abstract].
20. Pinto C., Di Fabio F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007, 18(3):510-517.
21. Pinto C., Di Fabio F., Barone C., et al. Phase II of cetuximab in combination with cisplatin/docetaxel as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (DOCETUX study). Br J Cancer 2009, 101(8):1261-1268.
22. Han S.W., Oh D.Y., Im S.A., et al. Phase II study and biomarker analysis of cetuximab in combination with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009, 100(2):298-304.
23. Lordick F., Lorenzen S., Hegewisch-Becker S., et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the AIO. Br J Cancer 2010, 102(3):500-505.
24. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Invest New Drugs. DOI: 10.1007/s10637-009-9363-0.
25. Kanzler S., Trarbach T., Seufferlein T., et al. Cetuximab with irinotecan/folinic acid/5-FU as first line treatment in advanced gastric cancer: a nonrandomized multicenter AIO phase II study. J Clin Oncol 2009, 27:4534. [Abstract].
26. Yeh K., Hsu C., Hsu C., et al. Phase II study of cetuximab plus weekly cisplatin and 24-h infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. J Clin Oncol 2009, 27:4567. [Abstract].
27. Zhang X., Xu J., Shen L., et al. A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer. Proc GI ASCO 2009, LBA39.
28. Woell E., Greil R., Eisterer W., et al. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial of the AGMT. J Clin Oncol 2009, 27:4538. [Abstract].
29. Rao S., Starling N., Cunningham D., et al. Phase I study of epirubicin, cisplatin and capecitabin plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2008, 99:868-874.
30. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitutumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25:1658-1664.
31. Herbst R.S., Fukuoka M., Baselga J. A novel targeted approach to treating cancer. Nat Rev Cancer 2004, 4:956-965.
32. Rojo F., Tabernero J., Albanell J., et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006, 24(26):4309-4316.
33. Dragovich T., McCoy S., Fenoglio-Preiser C.M., et al. Phase II trial of erlotinib in gastro-oesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006, 24:4922-4927.
34. Lordick F., Bang Y.K., Kang Y.K., et al. HER2-positive advanced gastric cancer: similar HER-2 positivity levels to breast cancer. Eur J Cancer 2007, A130.
35. Yano T., Doi T., Ohtsu A., et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006, 15(1):65-71.
36. Gravalos C., Marquez A., Garcia-Carbonero R., et al. Correlation between Her2/neu over-expression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study. Gastrointestinal Cancer Symposium 2007, 120:A89.
37. Kang Y., Bang Y., Lordick F., et al. Incidence of gastric and gastro-esophageal cancer in the ToGa trial: correlation with HER2 positivity. Gatrointestinal Cancers Symposium 2008, 75:A11.
38. Tanner M., Hollmen M., Junttila T.T., et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16:227-273.
39. Park D.I., Yun J.W., Park J.H., et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006, 51:1371-1379.
40. Kim S.Y., Kim H.P., Kim Y.J., et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008, 32:89-95.
41. Fujimoto-Ouchi K., Sekiguchi F., Yasuno H., et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 2007, 59:795-805.
42. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010, 376:687-697.
43. Geyer C.R., Foster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
44. Iqbal S., Goldman B., Lenz H.J., et al. A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007, 25:4621. [Abstract].
45. Hecht M., Urba S., Koehler M., et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarkers analuses. Proc GI ASCO 2008, 43. [Abstract].
46. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
47. Maeda K., Chunf Y.S., Ogawa T., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858-863.
48. Yoshikawa T., Tsuburaya A., Kobayashi O., et al. Plasma concentration of VEGF and bVEGF in patients with gastric carcinoma. Cancer Lett 2000, 153:7-12.
49. Hurwitz H., Fahrenbacher L., Novotny W.F., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
50. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non small cell lung cancer. N Engl J Med 2006, 355:2542-2550.
51. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
52. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006, 23(33):5201-5206.
53. Kelsen D., Jhawer M., Ilson D., et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: results of a phase II clinical trial. J Clin Oncol 2009, 27:4512. [Abstract].
54. El-Rayes B.F., Zalupski M., Bekai-Saab T., et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010, 10.1093/annonc/mdq065.
55. Enzinger P., Ryan D., Regan E., et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol 2008, 26:4552. [Abstract].
56. Cohenuram M.K., Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal, gastroesophageal (GE) and gastric cancer (G) adenocarcinoma: a single istitution's initial clinical experience. Proc GI ASCO 2008, 74.
57. Enzinger P., Fidias P., Meyerhardt J., et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer. Proc GI ASCO 2006, 68. [Abstract].
58. Van Cutsem E., Shah M., Kang Y., et al. Randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo as 1st-line therapy in patients with advanced gastric cancer (AVAGAST update). Ann Oncol 2010, 21(Suppl. 8):713P. [Abstract]. 10.1093/annonc/mdq514.
59. Shah M., Kang Y., Ohtsu A., et al. Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab+capecitabine/cisplatin in patients with advanced gastric cancer. Ann Oncol 2010, 21(Suppl. 8):174PD. [Abstract]. 10.1093/annonc/mdq514.
60. Spratlin J.L., Cohen R.B., Eadens M., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28(5):780-787.
61. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
62. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomized controlled trial. Lancet 2006, 368:1329-1338.
63. Bang Y.J., Kang Y.K., Kang W.K., et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2010, 10.1007/s10637-010-9438-y.
64. Moehler M., Hartmann J.T., Lordick F., et al. Sunitinib in patients with chemorefractory metastatic gastric cancer: preliminary results of an open-label, prospective non-randomized multicentre AIO Phase II trial. Proc GI ASCO 2009, 61.
65. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
66. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
67. Kim C., Lee J., Choi Y., et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2010, 10.1007/s10637-010-9531-2.
68. Sun W., Powell M., O'Dwyer P., et al. A phase II study: combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction adenocarcinoma (ECOG 5203). J Clin Oncol 2010, 28(18):2947-2951.
69. Weinstein I.B., Joe A. Oncogene addiction. Cancer Res 2008, 68:3077-3080. [Discussion 3080].
70. Cervantes A., Rodriguez Braun E., Perez Fidalgo A., et al. Molecular biology of gastric cancer. Clin Transl Oncol 2007, 9:208-215.
71. Ooi C.H., Ivanova T., Wu J., et al. Oncogenic pathway combination predict clinical prognosis in gastric cancer. PloS Genet 2009, 5:e1000676?.